Financial Information
This section of the Karyopharm Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Karyopharm Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQKPTI
| Beta | 0.31 |
|---|---|
| Shares Outstanding | 75.1M |
| Average Volume (10 days) | 1.6M |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Strong Buy |
|---|
| Strong Buy | 5 | |
|---|---|---|
| Buy | 1 | |
| Hold | 1 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Michael G. Kauffman Director, Chief Executive Officer | (4,000) Sell Mar 18, 2021 |
|---|---|
Sharon Shacham President & CSO | (4,000) Sell Mar 18, 2021 |
Michael Mason SVP, CFO & Treasurer | 22,013 Acquire Feb 25, 2021 |
Michael G. Kauffman Director, Chief Executive Officer | 57,200 Acquire Feb 25, 2021 |
Ran Frenkel EVP, Chief Dev. Officer | 22,013 Acquire Feb 25, 2021 |